Reply to M.-E. Percival et al and L.B. Saltz

Comment

John D Hainsworth et al. J Clin Oncol. 2013.

. 2013 Jul 1;31(19):2514-5.

doi: 10.1200/JCO.2013.49.6695.

No abstract available

Comment on

Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA. Hainsworth JD, et al. J Clin Oncol. 2013 Jan 10;31(2):217-23. doi: 10.1200/JCO.2012.43.3755. Epub 2012 Oct 1. J Clin Oncol. 2013. PMID: 23032625 Clinical Trial.
Role of expression profiling in carcinoma of unknown primary remains unknown.
Saltz LB. Saltz LB. J Clin Oncol. 2013 Jul 1;31(19):2513-4. doi: 10.1200/JCO.2013.49.2264. Epub 2013 Jun 3. J Clin Oncol. 2013. PMID: 23733754 No abstract available.
Biased view of the role of site-specific therapy in carcinoma of unknown primary.
Percival ME, Colevas AD. Percival ME, et al. J Clin Oncol. 2013 Jul 1;31(19):2512-3. doi: 10.1200/JCO.2013.49.5036. Epub 2013 Jun 3. J Clin Oncol. 2013. PMID: 23733770 No abstract available.